Breaking News Instant updates and real-time market news.

CBS

CBS

$56.74

0.89 (1.59%)

, NFLX

Netflix

$280.27

14.27 (5.36%)

17:14
02/15/18
02/15
17:14
02/15/18
17:14

CBS says loss of Thursday night football won't hurt retrans fees

Says not concerned about Netflix (NFLX) stealing talent. Says Netflix, Amazon (AMZN) calling about "Twilight Zone" rights.

CBS

CBS

$56.74

0.89 (1.59%)

NFLX

Netflix

$280.27

14.27 (5.36%)

AMZN

Amazon.com

$1,461.76

10.71 (0.74%)

  • 15

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 05

    Mar

  • 18

    Mar

  • 19

    Mar

CBS CBS
$56.74

0.89 (1.59%)

02/12/18
BRRR
02/12/18
NO CHANGE
BRRR
Potential reunion with CBS looms over Viacom fundamentals, says Barrington
Barrington analyst James Goss noted that Viacom (VIAB), which reported Q1 earnings last Thursday, beat the firm's EPS estimate, but fell 4% short of its revenue estimate, mainly due to a larger-than-expected decline in the revenue rate for Paramount. Godd reiterated a Market Perform rating on Viacom, saying that while the company's strategy will push it in a favorable direction, in the near term the primary catalyst appears to be the chance to recombine with CBS (CBS).
01/30/18
DBAB
01/30/18
NO CHANGE
Target $90
DBAB
Buy
Standalone or merger, Deutsche sees CBS shares going higher
Deutsche Bank analyst Bryan Kraft laid out his analysis for CBS (CBS) shares under different merger scenarios. The analyst values the stock at $90 in 12 months should CBS remain independent. In a merger with Viacom (VIAB), the analyst's pro forma 12-month valuation has the stock also worth $90. Kraft also analyzed a three-way merger transaction which combines CBS, Viacom and Lionsgate (LGF.A). Under this scenario, the analyst values CBS shares at $96 on a 12-month basis. Kraft has a Buy rating on CBS with a $90 price target.
02/09/18
RBCM
02/09/18
UPGRADE
Target $35
RBCM
Sector Perform
Viacom upgraded to Sector Perform at RBC on increasing likelihood of CBS deal
As reported earlier, RBC Capital analyst Steven Cahall upgraded Viacom (VIAB) to Sector Perform and raised his price target to $35 from $23, saying the combination with CBS (CBS) is increasingly likely. Cahall says he has been negative on Viacom for about two years based on the view of its networks being more at risk than peers from a "deteriorating ecosystem". Now that the merger with CBS is back on "likely in the coming months", the analyst contends, the transaction multiples near market prices would justify a more constructive view.
02/12/18
BMOC
02/12/18
NO CHANGE
Target $34
BMOC
Market Perform
Viacom price target raised to $34 from $27 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Viacom (VIAB) to $34, saying he remains "impressed" by the management's turnaround at the company, as seen in its better affiliate fee outlook, upcoming "direct to consumer" product launch, acquisitions of Vidcon and WHOSAY, and stronger international growth. The analyst also keeps his Market Perform rating, citing limited visibility around a potential CBS (CBS) deal as well as the company's asset mix remaining challenging.
NFLX Netflix
$280.27

14.27 (5.36%)

01/29/18
MKMP
01/29/18
NO CHANGE
Target $320
MKMP
Buy
Netflix price target raised to $320 from $245 at MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Netflix to $320 and kept his Buy rating after last week's "blow-out" results and earnings. The analyst contends that the peak for subscription additions is still a few years away and believes that investors underestimate the global appeal for the company's content, the expanding content investment driving higher consumer demand, and the internet-driven scale of content investment.
01/24/18
ARGS
01/24/18
NO CHANGE
ARGS
Hold
Netflix valuation 'significantly above peers', says Argus
Argus analyst Joseph Bonner keeps his Hold rating on Netflix while raising his FY18 EPS estimated to $2.73 from $2.01 after the company's latest earnings report. Bonner warns however that while Netflix subscription count is benefiting from a "secular growth of internet-delivered on-demand video", the company is also taking on more debt and burning through cash while attracting a host of competitors that include its own suppliers - Time Warner (TWX), Disney (DIS), and HBO - along with "deep-pocketed" rivals AT&T (T), Amazon (AMZN), Facebook (FB), and Google (GOOGL). The analyst adds that the valuation metrics on Netflix are also significantly higher than peers at a trailing EV/EBITDA multiple of 124-times - well above both the peer average of 29-times and Amazon's 50-times.
02/09/18
RHCO
02/09/18
DOWNGRADE
Target $31
RHCO
Hold
Lionsgate downgraded to Hold from Buy at SunTrust
SunTrust analyst Matthew Thornton downgraded Lionsgate (LGF.B) to Hold from Buy and lowered his price target to $31 from $36 after the company lowered its 3-year OIBDA growth outlook to 7.8% from about 13% amid accelerated investment in Starz and international divisions. Thornton notes that while the added spending is justifiable, the multiple needs to reflect the updated model as confidence in more back-end loaded guidance has been shaken. Among his areas of concern, Thornton also lists "accelerating mix shift to originals from licensed content", impact of Netflix (NFLX) on box office and competition for projects, and impact on Starz from bundling deals such as T-Mobile (TMUS) with Netflix and AT&T (T) with HBO.
02/14/18
RHCO
02/14/18
NO CHANGE
Target $270
RHCO
Hold
Netflix price target raised to $270 from $175 at SunTrust
SunTrust analyst Matthew Thornton raised his price target on Netflix to $270 after further evaluating his FY18 revenue, EBIT, and EPS growth view following Q4 results, with upward revisions driven by expectations of higher subscription adds, higher ARPU, and lower tax rates. The analyst keeps his Hold rating however, noting the risks of intensifying competition for subscribers, cost of content, and the renegotiations with U.S ISP's in the coming years.
AMZN Amazon.com
$1,461.76

10.71 (0.74%)

02/15/18
BERN
02/15/18
NO CHANGE
BERN
Walgreens/AmerisourceBergen deal a reaction to potential Amazon disruption, says Bernstein
Bernstein analyst Lance Wilkes sees a potential Walgreens (WBA)/AmerisourceBergen (ABC) deal as being a strategic reaction to gross margin pressures and potential disruption from Amazon (AMZN). His initial view is neutral to this deal, as he does not see it as strategically attractive, given his long-term concerns on the distributor role given his expectation of Amazon disruption to retail pharmacy. Wilkes would expect near-term synergies to be more limited, given the existing relationships between the companies and Walgreens's attractive economics already being achieved through the generic consortium.
02/15/18
SBSH
02/15/18
NO CHANGE
Target $96
SBSH
Buy
TJX concerns brings buying opportunity, says Citi
Citi analyst Paul Lejuez says sentiment has turned cautious on TJX (TJX) following the company's weak Q3 comp. The stock has underperformed most Specialty Softlines peers over the past three months and the multiple gap with Ross Stores (ROST) is now the widest it has been in 10 years, Lejuez tells investors in a research note. He believes the concerns weighing on TJX shares presents a buying opportunity. The analyst feels the company can quickly fix the fashion miss that dragged Marmaxx's comp down in Q3. He points out that the company has been winning market share along with Amazon.com (AMZN). It's the weaker players, like mall-based department stores, that are losing to Amazon, Lejuez argues. He keeps a Buy rating on TJX with a $96 price target.
02/14/18
BARD
02/14/18
NO CHANGE
Target $9
BARD
Neutral
ChannelAdvisor outlook likely to weigh on sentiment, says Baird
Baird analyst Colin Sebastian noted ChannelAdvisor (ECOM) missed Q4 estimates and cited non-core marketplace struggles as the cause. The analyst was positive on the company's improved performance across both the eBay (EBAY) and Amazon (AMZN) channels and is a positive for growth. Sebastian considers ChannelAdvisor a "show-me" story and maintained his Neutral rating while lowering his price target to $9 from $10 on the shares.
02/14/18
JEFF
02/14/18
NO CHANGE
JEFF
Amazon focusing on bolstering medical device distribution, says Jefferies
Yesterday's Wall Street Journal report and a recent scan of job postings still point to Amazon.com's (AMZN) focus on bolstering its medical device/supplies distribution capabilities, specifically targeting hospitals, Jefferies analyst Brian Tanquilut. These postings support a negative thesis for Cardinal Health (CAH), Owens & Minor (OMI) and Premier's (PINC) medical supplies businesses, the analyst adds. Further, he sees the news as an incremental positive for AmerisourceBergen (ABC), McKesson (MCK), CVS Health (CVS) and Walgreens Boots Alliance (WBA) since it further supports the view that Amazon isn't looking to enter the prescription business near-term.

TODAY'S FREE FLY STORIES

03:05
12/17/18
12/17
03:05
12/17/18
03:05
General news
FX Update: Narrow ranges have prevailed »

FX Update: Narrow ranges…

FII

Federated Investors

$24.65

-0.02 (-0.08%)

21:40
12/16/18
12/16
21:40
12/16/18
21:40
Initiation
Federated Investors initiated at Gabelli »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIII

G-III Apparel

$28.68

-0.29 (-1.00%)

21:37
12/16/18
12/16
21:37
12/16/18
21:37
Upgrade
G-III Apparel rating change at Stifel »

G-III Apparel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

21:34
12/16/18
12/16
21:34
12/16/18
21:34
Upgrade
Calyxt rating change at Goldman Sachs »

Goldman upgrades Calyxt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

20:23
12/16/18
12/16
20:23
12/16/18
20:23
Upgrade
Calyxt rating change at Goldman Sachs »

Calyxt upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

, EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

20:08
12/16/18
12/16
20:08
12/16/18
20:08
Recommendations
Crestwood Equity, EQT Midstream Partners analyst commentary at Goldman Sachs »

Goldman upgrades…

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$131.02

-2.26 (-1.70%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Downgrade
Illinois Tool Works rating change at Deutsche Bank »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$118.36

0.46 (0.39%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Upgrade
Stanley Black & Decker rating change at Deutsche Bank »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

, AET

Aetna

$0.00

(0.00%)

19:31
12/16/18
12/16
19:31
12/16/18
19:31
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

INCY

Incyte

$66.24

-1.04 (-1.55%)

AET

Aetna

$0.00

(0.00%)

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

HNT

Health Net

$0.00

(0.00%)

HUM

Humana

$300.41

-12.09 (-3.87%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

SNE

Sony

$51.32

-0.88 (-1.69%)

GOOG

Alphabet

$1,041.68

-21.44 (-2.02%)

GOOGL

Alphabet Class A

$1,050.62

-23.36 (-2.18%)

AAPL

Apple

$165.48

-5.45 (-3.19%)

BAC

Bank of America

$24.49

0.1 (0.41%)

BLK

BlackRock

$382.25

-5.29 (-1.37%)

CAT

Caterpillar

$126.78

0.79 (0.63%)

CVX

Chevron

$113.84

-2.15 (-1.85%)

DDAIF

Daimler AG

$0.00

(0.00%)

DAL

Delta Air Lines

$53.50

-0.03 (-0.06%)

ET

Energy Transfer LP

$14.08

-0.5 (-3.43%)

TOL

Toll Brothers

$32.23

-0.4 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 10

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 19

    Feb

  • 24

    Feb

  • 03

    Mar

EQT

EQT Corporation

$19.40

-0.78 (-3.87%)

18:54
12/16/18
12/16
18:54
12/16/18
18:54
Periodicals
EQT's board to seek meeting with Rice brothers, Reuters reports »

EQT Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

, EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

18:31
12/16/18
12/16
18:31
12/16/18
18:31
Downgrade
EQT Midstream Partners, EQGP Holdings rating change at Goldman Sachs »

EQT Midstream downgraded…

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

18:28
12/16/18
12/16
18:28
12/16/18
18:28
Upgrade
Crestwood Equity rating change at Goldman Sachs »

Crestwood Equity upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

17:52
12/16/18
12/16
17:52
12/16/18
17:52
Hot Stocks
Innovent, Incyte announce agreement for three clinical-stage candidates in China »

Incyte and Innovent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

NSANY

Nissan

$0.00

(0.00%)

, RNLSY

Renault

$0.00

(0.00%)

17:14
12/16/18
12/16
17:14
12/16/18
17:14
Periodicals
Renault seeking Nissan shareholder meeting amid Ghosn crisis, Reuters says »

Renault (RNLSY) requested…

NSANY

Nissan

$0.00

(0.00%)

RNLSY

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

T

AT&T

$30.24

0.33 (1.10%)

, CMCSA

Comcast

$36.32

-0.43 (-1.17%)

16:48
12/16/18
12/16
16:48
12/16/18
16:48
Hot Stocks
Box Office Battle: 'Spider-Verse' wins weekend with $35M »

Sony's (SNE)…

T

AT&T

$30.24

0.33 (1.10%)

CMCSA

Comcast

$36.32

-0.43 (-1.17%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.32

-0.88 (-1.69%)

FOX

21st Century Fox

$48.79

-0.09 (-0.18%)

FOXA

21st Century Fox

$49.06

-0.07 (-0.14%)

LGF.A

Lionsgate

$15.59

-0.16 (-1.02%)

DIS

Disney

$112.21

-1.17 (-1.03%)

VIAB

Viacom

$28.56

-0.31 (-1.07%)

VIA

Viacom

$31.23

-0.4 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 30

    Jan

  • 20

    Mar

ELGX

Endologix

$0.71

0.0232 (3.39%)

16:17
12/16/18
12/16
16:17
12/16/18
16:17
Conference/Events
Endologix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$0.19

-0.0111 (-5.63%)

16:11
12/16/18
12/16
16:11
12/16/18
16:11
Conference/Events
Precipio to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$25.15

-1.1 (-4.19%)

16:08
12/16/18
12/16
16:08
12/16/18
16:08
Conference/Events
Mesabi Trust to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$1.19

-0.1 (-7.75%)

16:02
12/16/18
12/16
16:02
12/16/18
16:02
Conference/Events
Melinta Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$75.63

-1.32 (-1.72%)

15:55
12/16/18
12/16
15:55
12/16/18
15:55
Periodicals
Exxon Mobil shareholders call for greenhouse gas reduction targets, Reuters says »

A number of institutional…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$275.59

-4.93 (-1.76%)

, CNC

Centene

$127.55

-5.3 (-3.99%)

13:16
12/16/18
12/16
13:16
12/16/18
13:16
Periodicals
Health stocks preparing for market jolt after Obamacare ruling, Bloomberg says »

U.S. health-care stocks…

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

HUM

Humana

$300.41

-12.09 (-3.87%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

HNT

Health Net

$0.00

(0.00%)

AET

Aetna

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

  • 05

    Feb

  • 19

    Feb

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

13:02
12/16/18
12/16
13:02
12/16/18
13:02
Hot Stocks
Jeld-Wen announces final ruling in Steves & Sons litigation, to appeal decision »

Jeld-Wen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRA

Atara Biotherapeutics

$41.78

-0.74 (-1.74%)

12:55
12/16/18
12/16
12:55
12/16/18
12:55
Hot Stocks
Atara Biotherapeutics presents positive efficacy, safety results for EBV + LMS »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$133.95

2.595 (1.98%)

12:41
12/16/18
12/16
12:41
12/16/18
12:41
Hot Stocks
BeiGene announces updated Phase 1A/1B data on tislelizumab »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

12:35
12/16/18
12/16
12:35
12/16/18
12:35
Hot Stocks
Jeld-Wen ordered to divest Pennsylvania plant to restore competition »

Federal Judge Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.